Trial Profile

A Phase 1B, Open-Label, Dose-Escalation Study of the Safety and Efficacy of an Anti-CD38 Antibody Drug Conjugate (STI-6129) in Patients With Advanced Solid Tumors

Status: Not yet recruiting

Phase of Trial: Phase I

Latest Information Update: 20 Oct 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs STI 6129 (Primary)
Indications Colorectal cancer; Head and neck cancer; Lung cancer; Oesophageal cancer; Solid tumours; Squamous cell cancer
Focus Adverse reactions
Sponsors Sorrento Therapeutics

Most Recent Events

24 Jun 2019 New trial record
19 Jun 2019 According to an Sorrento Therapeutics Media release, the company announces intention to submit IND application for STI 6129 in second half of 2019.
19 Jun 2019 According to an Sorrento Therapeutics Media release, the company plans initiation of clinical trials for STI 6192 in Haematological malignancies by the end of 2019.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com